Date: August 3rd 2022
Your Name:_Kenji Nakahama
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
Payment for expert testimony	X None	
Support for attending meetings and/or travel	<u>X</u> None	
Patents planned, issued or pending	_ <u>X</u> None	
Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
Stock or stock options	<u>X</u> None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
Other financial or non- financial interests	XNone	
		lowing box:
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X None

Date:_August 3 rd 2022
our Name:_ <u>Masahiko Osawa</u>
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
mall-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None	
3	Royalties or licenses	X None	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>X</u> None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	_ <u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	X None	
	ease summarize the above co		lowing box:

Date:_August 3 rd 2022
Your Name:_ Motohiro Izumi
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): <u>TLCR-22-496</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All C II	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>X</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or pending	_ <u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co		lowing box:

Date:_August 3 rd 2022
Your Name: Naoki Yoshimoto
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): <u>TLCR-22-496</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	XNone X None	
	testimony	None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	<u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	XNone	
Please summarize the above conflict of interest in the following box:			
	Naoki Yoshimoto has nothing to	o disclose.	

Date:_August 3 rd 2022
Your Name:_ Akira Sugimoto
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): <u>TLCR-22-496</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	<u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	XNone	
	ase summarize the above co		lowing box:

Date:_August 3rd 2022
Your Name:_ Hiroaki Nagamine
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): <u>TLCR-22-496</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	X None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	<u>X</u> None	
	ease summarize the above co		lowing box:

Date:_August 3rd 2022
Your Name:_ <u>Koichi Ogawa</u>
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): <u>TLCR-22-496</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	lectures, presentations,	X None		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_ <u>X</u> None		
	testimony			
_				
7	Support for attending	_ X None		
	meetings and/or travel			
8	Patents planned, issued or	X None		
	pending			
9	Participation on a Data	X None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	<u>X</u> None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	X None		
11	Stock of Stock options	<u>^</u> None		
12	Receipt of equipment,	X None		
	materials, drugs, medical	X_None		
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
	Koichi Ogawa has nothing to di	sciose.		

Date:_August 3rd 2022
Your Name:_ Yoshiya Matsumoto
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present	<u>X</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time mint for this item.		
		Time (management)	26
	-	Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	XNone		
6	testimony	<u>X</u> None		
7	Support for attending meetings and/or travel	_ <u>X</u> None		
8	Patents planned, issued or pending	_ <u>X</u> None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None		
11	Stock or stock options	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None		
13	Other financial or non- financial interests	XNone		
Ple	Please summarize the above conflict of interest in the following box:			
	Yoshiya Matsumoto has nothin	g to disclose.		

Date:_August 3rd 2022
Your Name:_ Kenji Sawa
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present	<u>X</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time mint for this item.		
		Time (management)	26
	-	Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	_ X None	

		,	<u> </u>
.0	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., DAICHI SANKYO COMPANY LIMITED	Personal fees
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	<u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	<u>X</u> None	

Please summarize the above conflict of interest in the following box:

Kenji Sawa reports personal fees from Chugai Pharmaceutical Co., Ltd, Nippon Boehringer Ingelheim Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED outside the submitted work.	

Please place an "X" next to the following statement to indicate your agreement:

Date:_August 3rd 2022	
Your Name:_ <u>Yoko Tani</u>	
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy	in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3	
Manuscript number (if known): TLCR-22-496	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	X None	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated	<u>X</u> None	
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	X None	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	v	
6	Payment for expert	X None	
	testimony		
7	Support for attending	V Name	
,	Support for attending meetings and/or travel	_ <u>X</u> None	
	meetings and/or traver		
8	Patents planned, issued or	X None	
O	pending	_ <u>A</u> None	
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	<u>X</u> None	
	writing, gifts or other		
	services		
13	Other financial or non-	<u>X</u> None	
	financial interests		
DI-		auflick of inkonack in the fal	lawing have
PIE	ease summarize the above c	onflict of interest in the fol	iowing box:
	Yoko Tani has nothing to disclo	<u></u>	
	TORO TAIN HAS HOUTHING TO GISCIO	JC.	

Date:_August 3rd 2022
Your Name:_ <u>Hiroyasu Kaneda</u>
Manuscript Title: <u>SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non</u>
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD, Bristol-Myers Squibb K.K.	Personal fees
6	Payment for expert testimony	_ <u>X</u> None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	_ <u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

Hiroyasu Kaneda reports personal fees from MSD, Ono Pharmaceutical Co., Ltd.; Bristol-Myers Squibb K.K. Chugai Pharmaceutical Co., Ltd.; outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date:_August 3rd 2022
Your Name:_Shigeki Mitsuoka
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Bristol-Myers Squibb K.K., Taiho Pharmaceteutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Lilly, AstraZeneca K.K.	Personal fees
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	X None	

Please summarize the above conflict of interest in the following box:

S Mitsuoka reports personal fees from MSD K.K., Ono Pharmaceutical Co., Ltd.; Bristol-Myers Squibb K.K.; Taiho Pharmaceutical Co., Ltd.; Kyowa Hakko Kirin Co., Ltd.; Lilly; Chugai Pharmaceutical Co., Ltd.; and AstraZeneca K.K. outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date:_August 3rd 2022
Your Name:_Tetsuya Watanabe
Manuscript Title: <u>SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non-</u>
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	_ X None	

5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ <u>X</u> None	
	testimony		
7	Support for attending	_ X None	
	meetings and/or travel		
	Detects also and issued an	Y	
8	Patents planned, issued or pending	_ <u>X</u> None	
	Pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or	X None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	<u>X</u> None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	X None	
13	financial interests	<u>X</u> None	
	initialities intereses		
Ple	ease summarize the above o	onflict of interest in the fo	lowing box:
_			
	Tetsuya Watanabe has nothing	to disclose.	

Date:_August 3rd 2022
Your Name: Kazuhisa Asai
Manuscript Title: SP142 Evaluation Contributes to the Prediction of Immune Checkpoint Inhibitor Efficacy in Non
Small-Cell Lung Cancer with High PD-L1 Expression Assessed by 22C3
Manuscript number (if known): TLCR-22-496

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present	<u>X</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time mint for this item.		
		Time (management)	26
	-	Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	_ X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None		
6	Payment for expert testimony	X None		
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or pending	<u>X</u> None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> _None		
11	Stock or stock options	X None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None		
13	Other financial or non- financial interests	<u>X</u> None		
Ple	Please summarize the above conflict of interest in the following box:			
	Kazuhisa Asai has nothing to dis	sclose.		

Date:_August 3rd 2022		
Your Name:_ <u>Tomoya Kawaguchi</u>		
Manuscript Title: SP142 Evaluation	Contributes to the Prediction	n of Immune Checkpoint Inhibitor Efficacy in Non-
Small-Cell Lung Cancer with High PD	-L1 Expression Assessed by 2	<u>2C3</u>
Manuscript number (if known):	TLCR-22-496	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Ono Pharmaceutical Company, Chugai Pharmaceutical Company, AstraZeneca, Taiho Pharmaceutical Company, Boehringer Ingelheim Pharmaceutical, Bristol Myers Squibb, Lilly, Kyowa Kirin	Grants
3	Royalties or licenses	XNone	

4	Consulting fees	_ X None	
5	Payment or honoraria for lectures, presentations,	Chugai Pharmaceutical Co., Ltd., Ono	Personal fees
	speakers bureaus, manuscript writing or educational events	Pharmaceutical Co., Ltd., MSD, Bristol-Myers Squibb K.K., Taiho Pharmaceteutical Co., Ltd., Lilly, AstraZeneca K.K., Novartis, Pfizer, Boehringer Ingelheim Pharmaceutical	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	_ <u>X</u> None	
8	Patents planned, issued or pending	_ <u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

Tomoya Kawaguchi reports personal fees from MSD, Novartis, and Pfizer; grants and personal fees from Ono Pharmaceutical Company, Chugai Pharmaceutical Company, AstraZeneca, Taiho Pharmaceutical Company, Boehringer Ingelheim Pharmaceutical, Bristol Myers Squibb, and Lilly; and grants from Kyowa Kirin, outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement: